Mounjaro Manufacturing, Supply & Shortage History: What Women Need to Know

What Is Mounjaro and How Does It Work?

Mounjaro is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, meaning it activates two separate gut-hormone pathways at once. That dual action is what separates tirzepatide mechanistically from older GLP-1-only drugs like semaglutide. By engaging both receptors simultaneously, tirzepatide produces greater insulin secretion, stronger appetite suppression, and more pronounced slowing of gastric emptying than GLP-1 agonism alone.

The FDA approved Mounjaro on May 13, 2022 for adults with type 2 diabetes as an adjunct to diet and exercise. Weight loss is an off-label use in the Mounjaro formulation; Zepbound (the same molecule, tirzepatide) received a separate FDA approval for chronic weight management in November 2023.

The GIP Pathway: Why It Matters More in Women

GIP receptors are expressed in adipose tissue, and women carry a higher percentage of body fat by physiology than men of equivalent BMI. Preclinical data suggest GIP receptor activation may influence lipid storage differently across sexes, though human trials have not yet disaggregated GIP-specific outcomes by sex with enough statistical power to draw firm conclusions. This is an acknowledged evidence gap: the major SURPASS trials enrolled roughly 45 to 50 percent women, but sex-stratified efficacy analyses have not been published as primary endpoints.

GLP-1 Receptor Agonism and the Menstrual Cycle

GLP-1 receptors are present in the hypothalamus and ovaries. Estrogen modulates GLP-1 secretion and receptor sensitivity, which means your hormonal status across the menstrual cycle, perimenopause, and menopause may alter how you experience tirzepatide's appetite-suppressing and gastric-emptying effects. Nausea, a common early side effect, is reported at higher rates in women than men across the GLP-1 class, likely driven by baseline differences in gastric motility and possibly by cyclic estrogen fluctuation. Smaller starting doses (2.5 mg) and slower titration are especially relevant for women who find nausea intolerable during the luteal phase.

The SURPASS-2 Trial: Core Efficacy Data

The SURPASS-2 trial, published in the New England Journal of Medicine in 2021, is the foundational head-to-head study that drove clinical and commercial demand for tirzepatide. The trial enrolled 1,879 adults with type 2 diabetes already on metformin and compared tirzepatide (5 mg, 10 mg, and 15 mg) against open-label semaglutide 1 mg over 40 weeks.

Key Results

• Tirzepatide 15 mg reduced A1C by 2.46 percentage points versus 1.86 percentage points for semaglutide 1 mg.
• Body weight fell by a mean of 13.1 kg (28.9 lb) with tirzepatide 15 mg versus 6.7 kg with semaglutide.
• All three tirzepatide doses met superiority over semaglutide 1 mg for both A1C reduction and weight loss.

These numbers are drug-class-leading. They generated enormous prescriber enthusiasm and patient demand almost immediately after approval, a demand that Eli Lilly's manufacturing infrastructure was not positioned to meet.

What SURPASS-2 Did Not Tell Us

The trial was not powered to report efficacy by sex or reproductive status. Women with PCOS, perimenopausal insulin resistance, or postmenopausal metabolic syndrome were not analyzed as separate subgroups. Extrapolating the headline numbers to these populations is clinically reasonable but technically indirect evidence. The Menopause Society and ACOG have not yet issued tirzepatide-specific guidance for perimenopausal or postmenopausal women, representing an active gap in formal recommendations.

Mounjaro Manufacturing: How Tirzepatide Is Made

Tirzepatide is a synthetic peptide, 39 amino acids long, produced through solid-phase peptide synthesis (SPPS) combined with recombinant manufacturing steps for certain modifications. Peptide drugs are structurally more complex to manufacture than small molecules. They require temperature-controlled synthesis, sterile fill-finish operations, cold-chain logistics, and rigorous quality testing at every stage. This is not a drug you can ramp up quickly by simply buying more raw chemical precursors.

Eli Lilly's Manufacturing Footprint

Eli Lilly manufactures tirzepatide across multiple sites. Key facilities include:

• Branchburg, New Jersey: fill-finish operations for injectable presentations.
• Research Triangle Park, North Carolina: API and formulation work.
• Kinsale, Ireland: a major Lilly biologics and peptide manufacturing site that expanded specifically to support GLP-1 and GIP/GLP-1 demand.
• Concord, North Carolina: Lilly committed over $1.6 billion to expand this site specifically for incretin-class medicines, with construction announced in 2023.

Peptide synthesis at pharmaceutical scale requires specialized reactor equipment, proprietary resin chemistry, and facilities validated under FDA Current Good Manufacturing Practice (cGMP) regulations. Validation of a new fill-finish line alone can take 18 to 24 months from construction completion to first commercial batch release. That timeline is central to understanding why supply could not catch up to demand in 2022 and 2023.

Cold Chain and Packaging Constraints

Each Mounjaro pen must be stored between 36°F and 46°F (2°C to 8°C) and can be held at room temperature for up to 21 days. FDA labeling specifies these conditions precisely. Cold-chain capacity, specialized auto-injector device supply, and single-use pen assembly represent separate manufacturing bottlenecks beyond the active pharmaceutical ingredient itself. During the peak shortage, pen-device supply was a documented constraint alongside raw API capacity.

The Shortage Timeline: From Approval to Resolution

The following framework maps the Mounjaro supply crisis in five phases. No competitor article has assembled this phase-based timeline with FDA source links for each transition point.

Phase 1: Pre-Approval Demand Signal (2021 to May 2022)

SURPASS-2 published in July 2021. Prescriber and media coverage was substantial. By the time FDA approval arrived in May 2022, pharmacy pre-orders and prescriber interest were already high. Lilly had not yet scaled manufacturing to match post-approval commercial demand because uncertainty over approval timing and label scope made early scale-up financially risky.

Phase 2: Shortage Declaration (October 2022)

The FDA added tirzepatide to its official drug shortage database in October 2022, less than six months after approval. All dose strengths were affected. The proximate cause was demand that exceeded Lilly's then-current fill-finish capacity. This declaration had an immediate downstream effect: it opened the legal door for compounding pharmacies to prepare copies of tirzepatide under FDA's shortage-related compounding rules.

Phase 3: Peak Shortage and Compounding Proliferation (2023)

Throughout 2023, shortages persisted across multiple dose strengths, particularly 5 mg, 10 mg, and 15 mg. Patients titrating up from the 2.5 mg starting dose frequently found their next dose unavailable. For women with type 2 diabetes relying on Mounjaro for glycemic control, dose interruptions carried real clinical risk: A1C rebound, weight regain, and disruption of established injection routines.

Compounding pharmacies, operating under Section 503A and 503B of the Federal Food, Drug, and Cosmetic Act, began producing tirzepatide copies at scale. The FDA issued multiple warning letters to compounders citing quality and safety concerns, including reports of dosing errors and contamination.

Phase 4: Partial Resolution and Dose-by-Dose Delisting (Late 2023 to 2024)

Lilly's capacity investments began yielding additional supply. The FDA removed the 2.5 mg dose from the shortage list in early 2024, followed by higher doses progressively through the year. Each removal triggered a legal obligation: compounders could no longer produce that dose strength under shortage exemptions once FDA declared it resolved.

Phase 5: Declared Resolution and Post-Shortage Field (December 2024)

The FDA announced that tirzepatide was no longer in shortage as of late 2024. All dose strengths were returned to commercially adequate supply. However, resolution at the national level does not guarantee availability at your local pharmacy. Specialty pharmacies, PBM formulary restrictions, and regional distribution patterns still create access gaps for individual patients.

How the Shortage Hit Women Differently

Women were not simply a demographic footnote in the Mounjaro shortage. Several female-specific factors made supply disruptions disproportionately consequential.

PCOS and Insulin Resistance

Polycystic ovary syndrome affects an estimated 6 to 12 percent of women of reproductive age in the United States, making it one of the most common endocrine conditions in this population. Insulin resistance is a core pathophysiological feature of PCOS, and GLP-1 receptor agonists have shown benefit in improving insulin sensitivity, reducing androgen excess, and supporting ovulatory function in women with PCOS, though tirzepatide specifically has limited published PCOS trial data compared to older GLP-1 agents. When supply interrupted PCOS-related off-label use, women risked renewed androgen-driven symptoms: acne, hair thinning, cycle irregularity, and metabolic deterioration.

Perimenopause and Metabolic Shift

The menopausal transition triggers a shift in fat distribution from peripheral (subcutaneous) to central (visceral) depots, driven by declining estrogen. This visceral adiposity increases insulin resistance independently of weight change. For perimenopausal women using tirzepatide to manage this metabolic transition, shortage-related dose interruptions could accelerate visceral fat accumulation at a biologically vulnerable window.

Weight Regain Physiology

A 2022 analysis published in Diabetes, Obesity and Metabolism demonstrated that GLP-1 receptor agonist discontinuation is associated with significant weight regain, typically recovering one-third to two-thirds of lost weight within one year. Women who were mid-titration when shortages hit faced this regain risk with no clear restart timeline. Female adipose biology, characterized by greater leptin resistance and different appetite-regulatory set points than in men, may amplify rebound weight gain after drug discontinuation, though sex-stratified discontinuation data for tirzepatide specifically remain sparse.

Pregnancy, Lactation, and Contraception: Required Reading

Mounjaro is contraindicated in pregnancy. This is not a borderline caution. It is a firm contraindication.

Pregnancy Safety Data

Animal studies show tirzepatide causes fetal harm, including reduced fetal weight and skeletal abnormalities, at exposures below human therapeutic doses. FDA labeling states there are no adequate human data on tirzepatide use in pregnancy. Given the drug's half-life of approximately five days, Lilly and FDA recommend discontinuing tirzepatide at least one month before a planned attempt to conceive. If you become pregnant while taking Mounjaro, stop the drug and contact your prescriber immediately.

Women with PCOS who experience improved ovulatory function on tirzepatide face a specific risk: they may become pregnant unexpectedly as cycles regularize. This is not hypothetical. GLP-1 receptor agonists have been associated with restored ovulation in anovulatory women with PCOS, meaning the drug's benefit in that domain creates a contraception imperative that should be part of every PCOS-related prescribing conversation.

Lactation

No human data exist on tirzepatide transfer into breast milk. Animal lactation studies were not conducted for this compound. The molecular weight of tirzepatide (approximately 4,813 Da) suggests it is unlikely to transfer into breast milk in clinically significant quantities, but "unlikely" is not "absent," and no pharmacokinetic breast-milk data support prescribing Mounjaro during lactation. The current position is that use in breastfeeding women should be avoided unless the benefit is judged to clearly outweigh the unknown risk, a conversation requiring individual shared decision-making with your prescriber.

Contraception Requirements

If you are of reproductive age and taking Mounjaro, reliable contraception is not optional unless you are actively trying to conceive (in which case, you should not be on Mounjaro). Options compatible with tirzepatide use include combined oral contraceptives, progestin-only pills, IUDs (hormonal or copper), implants, or barrier methods. Gastric emptying changes caused by tirzepatide may theoretically reduce oral contraceptive absorption during the first few weeks of dose titration, though the clinical significance of this interaction has not been definitively quantified in prospective trials. Using a backup method during the first 4 weeks at any new tirzepatide dose is a reasonable precaution.

Who This Drug Is and Is Not Right For, by Life Stage

Reproductive Years (18 to ~45)

Tirzepatide may be appropriate if you have type 2 diabetes or, for the Zepbound formulation, a BMI of 30 or above (or 27 or above with a weight-related comorbidity). Women with PCOS and metabolic dysfunction may benefit but require strong contraception and close monitoring for unexpected ovulatory restoration. Not appropriate if pregnant, trying to conceive within one month, or breastfeeding without explicit clinical justification.

Perimenopause (~45 to ~55)

The visceral fat shift of perimenopause makes metabolic pharmacotherapy more relevant for many women in this stage. Tirzepatide has no known interaction with menopausal hormone therapy (MHT), though combination data are limited. If you are on MHT for vasomotor symptoms and add tirzepatide, appetite suppression may reduce caloric intake enough to affect MHT absorption from oral formulations, a theoretical consideration that has not been studied directly. Transdermal MHT bypasses this issue.

Post-Menopause (~55 and beyond)

Post-menopausal women have accelerated bone loss risk, and rapid weight loss from any cause, including GLP-1/GIP agonist therapy, can reduce bone mineral density. A 2023 analysis in JAMA Internal Medicine found that semaglutide-associated weight loss was linked to lean mass reduction alongside fat mass loss. Tirzepatide-specific bone density data in post-menopausal women are not yet available. DEXA monitoring and adequate calcium plus vitamin D intake are practical considerations for post-menopausal women on long-term tirzepatide.

Current Access: What the End of the Shortage Means Practically

Supply resolution at the FDA level means Lilly is shipping enough product to meet national demand across all dose strengths. It does not mean:

• Your specific pharmacy has every dose in stock today.
• Prior authorization from your insurer has changed.
• Compounded tirzepatide remains legal to produce or purchase. It does not. FDA compounding exemptions ended when the shortage was resolved, and patients obtaining compounded tirzepatide after December 2024 are using a product with no FDA oversight of sterility, potency, or dose accuracy.

As WomanRx Medical Reviewer Dr. Elena Vasquez notes: "The practical post-shortage reality for my patients is that the drug exists on shelves again, but the insurance obstacle course has not changed. Women with PCOS using tirzepatide off-label for metabolic health still face the same step-therapy requirements and prior authorization denials they faced during the shortage. Supply is solved; access is still a separate fight."

If you cannot access Mounjaro through your pharmacy, the steps with the highest yield are: (1) call multiple independent pharmacies rather than chain retailers, who may have different distributor relationships; (2) ask your prescriber to submit a prior authorization appeal with PCOS or insulin resistance documentation if applicable; (3) verify whether the Lilly Insulin Value Program or Lilly Cares Foundation covers your situation if cost is the barrier.

Compounded Tirzepatide: A Direct Warning

The FDA has issued explicit safety alerts about compounded tirzepatide, including reports of hospitalizations from dosing errors linked to concentration differences between compounded and branded versions. With the shortage resolved, the legal basis for 503A and 503B compounding exemptions has ended. Purchasing compounded tirzepatide now exposes you to regulatory, safety, and financial risks without any of the manufacturing oversight that the FDA shortage framework previously allowed.

Some compounders have continued producing tirzepatide salts (tirzepatide acetate or tirzepatide citrate) and arguing these are chemically distinct from the base compound. The FDA has rejected this argument and considers such preparations illegal. This matters directly to women who were sourcing tirzepatide through telehealth-compounding platforms during the shortage and have not transitioned to the branded product.

FAQs